^
Association details:
| Biomarker: | Chr del(11q) |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Gazyva (obinutuzumab) (CD20 inhibitor) + Calquence (acalabrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Ibrutinib and acalabrutinib ± obinutuzumab are preferred first-line therapy options for all patients including in high-risk subgroups such as those with del(11q) or del(17p)/TP53 mutation and unmutated IGHV.
